• Publications
  • Influence
Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator
Based on a lower intrinsic activity at D2 receptors and higher binding affinities for 5-HT1A/2A receptors than aripiprazole, brexpiprazoles would have a favorable antipsychotic potential without D2 receptor agonist- and antagonist-related adverse effects.
Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade
Using in vivo microdialysis methods in rats, the nonselective 5-HT2 receptor antagonist ketanserin was observed to produce a robust augmentation of citalopram-, fluoxetine-, and sertraline-induced elevations of hippocampal extracellular serotonin levels.
Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics
The data suggest that the combination of 5-HT6 antagonistic activity and the absence of antimuscarinic activity may represent key characteristics of the pharmacological profile for improved antipsychotic drugs for schizophrenia.
Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.
  • J. Arnt
  • Psychology, Biology
    Acta pharmacologica et toxicologica
  • 13 March 2009
It is concluded that CAR inhibition is a sensitive test for dopamine receptor antagonists, however, additional alpha-adrenergic activity found for some neuroleptics may contribute to the CAR inhibitory potency.
Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
Lu AE58054 is a selective antagonist of 5-HT(6)Rs with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia, and may be useful for the pharmacotherapy of cognitive dysfunction in disease states such as schizophrenia and Alzheimer's disease.